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Background. Few data are available regarding the immunogenicity and safety of the pandemic influenza vaccine
in immunocompromised patients. We evaluated the humoral response to the influenza A H1N1/09 vaccine in solid-
organ transplant (SOT) recipients, in patients with human immunodeficiency virus (HIV) infection, and in healthy
individuals.
Methods. Patients scheduled to receive the pandemic influenza vaccine were invited to participate. All
participants received the influenza A H1N1/09 AS03-adjuvanted vaccine containing 3.75 lg of hemagglutinin. SOT
recipients and HIV-infected patients received 2 doses at 3-week intervals, whereas control subjects received 1 dose.
Blood samples were taken at day 0, day 21, and day 49 after vaccination. Antibody responses were measured with the
hemagglutination inhibition assay (HIA) and a microneutralization assay.
Results. Twenty-nine SOT recipients, 30 HIV-infected patients, and 30 healthy individuals were included in the
study. Seroconversion measured by HIA was observed in 15 (52%) of 29 SOT recipients both at day 21 and day 49;
in 23 (77%) of 30 at day 21 and 26 (87%) of 30 at day 49 in HIV-infected patients, and in 20 (67%) of 30 at day 21
and in 23 (77%) of 30 at day 49 in control subjects (P 5 .12 at day 21 and P 5 .009 at day 49, between groups).
Geometric means of antibody titers were not significantly different between groups at day 21 or at day 49.
Conclusions. Influenza A H1N1/09 vaccine elicited a similar antibody response in HIV-infected individuals and
in control subjects, whereas SOT recipients had an overall lower response. A second dose of the vaccine only
moderately improved vaccine immunogenicity in HIV-infected patients.
BACKGROUND
InMarch 2009, clustered cases of respiratory infection in
Mexico led to the discovery of a new subtype of in-
fluenza virus A H1N1 [1–3]. The virus spread rapidly
worldwide, and it was estimated that59million people
in the United States had been infected with the virus as
of February 2010. Although overall mortality associated
with influenza A H1N1/09 infection was considered to
be low [3], several groups of patients at risk for com-
plications were identified: pregnant women [4], young
people with chronic diseases [5] and immunocompro-
mised patients [6, 7].
Vaccination against influenza A H1N1/09 was
strongly recommended to patients at risk for compli-
cations. In particular, guidelines endorsed by the World
Health Organization [8] recommended vaccination
against influenza virus in human immunodeficiency
virus (HIV)–infected individuals and in solid-organ
transplant (SOT) recipients because of the potential risk
of complications in these patients.
Several different preparations of the influenza A
H1N1/09 vaccine were available for large-scale vacci-
nation. In the United States, 2 doses of nonadjuvanted
vaccine containing 15 lg of hemagglutinin were rec-
ommended for immunocompromised patients, whereas
in Europe a vaccine adjuvanted with a squalen oil-in-
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water emulsion (either MF59 or AS03) and a lower dose of
antigen was preferably used. Although some studies have com-
pared the immunogenicity of these different vaccines in healthy
children and adults [9–14], few data have been published re-
garding their use in immunocompromised patients [15]. In
particular, there was no previous data on the use of the AS03
adjuvant in HIV-infected individuals and SOT recipients, and
therefore the safety and efficacy of the vaccine with use of this
adjuvant was unknown. Also, there was uncertainty regarding
the need for a second dose of the vaccine in patients with im-
paired immunity.
On November 2009, the Swiss Federal Office of Public Health
(FOPH) provided the influenza A H1N1/09 AS03-adjuvanted
vaccine free of charge to all patients at risk for influenza, in-
cluding HIV-infected individuals, SOT recipients, and health
care workers. We prospectively assessed the safety and immu-
nogenicity of this vaccine in these populations.
METHODS
Patients
Patients observed at the outpatient clinics of the Transplantation
Centre and the Infectious Diseases Service from the University
Hospital of Lausanne (CHUV) (Lausanne, Switzerland) were
approached by nursing and medical staff to recommend the
administration of the influenza A H1N1/09 vaccine. If the pa-
tients expressed interest in receiving the vaccine, then the study
was presented by the investigators to the patients. Control sub-
jects were enrolled from amongmembers the staff of the hospital
who were undergoing regular vaccination by announcing the
study during staff meetings. Inclusion criteria for the SOT re-
cipients group were age>18 years,>3 months after kidney and/
or liver transplantation, creatinine clearance level .30 mL/min,
and no episode of acute rejection over the previous month. In-
clusion criteria for the HIV group were age >18 years and
a CD41 T cell count .200 cells/mL. Inclusion criteria for the
control group were age >18 years and absence of an immuno-
suppressive condition. Exclusion criteria for all groups were
pregnancy, allergy to egg, and previous serious adverse event
related to receipt of influenza vaccine. Patients and control
subjects who received the seasonal influenza vaccine before or
simultaneously with the pandemic influenza vaccine were al-
lowed to participate in the study. All subjects provided written
informed consent. The study was approved by the local in-
stitutional review board.
The study intervention consisted in obtaining blood samples
before vaccination (day 0), at day 21 after vaccination (ie, before
the second dose of vaccine in the HIV-infected and SOT re-
cipients groups), and at day 49 after the first vaccination. Sub-
jects were contacted by telephone to determine whether they had
experienced adverse events related to vaccination 24 h, 48 h, and
7 days after receipt of each vaccination. All adverse events were
graded according to the following classification: mild, defined as
no interference with normal activities; moderate, defined as some
interference with normal activities; and severe, defined
as preventing subjects from engaging in normal daily activities.
After vaccination, patients were observed during a 6-month pe-
riod for the development of influenza infection, and they were
instructed to return to the outpatient clinics in case of symptoms
compatible with influenza infection (respiratory illness, temper-
ature.38C, or myalgia). A real-time polymerase chain reaction
for influenza AH1N1/09 from a nasopharyngeal swab sample was
performed in all cases of clinical suspicion of influenza.
Vaccine
The vaccine used in this study was the influenza A H1N1/09
AS03-adjuvanted vaccine (Pandemrix; GlaxoSmithKline). The
vaccine was composed from a split inactivated A/California/07/
2009 (H1N1)–derived strain of influenza virus containing 3.75
lg of hemagglutinin antigen. The AS03 adjuvant was composed
of squalene (10.69 mg), DL-a-tocopherol (11.86 mg), and
polysorbate 80 (4.86 mg). The vaccine was provided free of
charge by the FOPH by 16 November 2009. SOT recipients and
HIV-infected patients received 2 doses at a 3-week interval,
whereas control subjects received 1 dose.
Clinical Definitions
We used standard clinical definitions to evaluate the response to
the vaccine. Seroconversion rate was defined as the rate of pa-
tients with >4-fold increase in antibody titers against influenza
A H1N1/09 after vaccination. Seroconversion factor was defined
as the level of increase in antibody titers before and after vacci-
nation. Seroprotection rate was defined as the percentage of pa-
tients with an antibody titer after vaccination of >32 measured
by hemagglutination inhibition assay (HIA) or>40 measured by
microneutralization. The European Medicines Agency (EMEA)
recommendations to evaluate the efficacy of the influenza vaccine
require a seroconversion rate of>40%, a seroconversion factor of
>2.5, and a seroprotection rate of >70%. The vaccination end
points were primarily evaluated using the HIA, because only this
assay has been correlated with vaccine protection.
Laboratory Methods
Antibody responses were detected by means of micro-
neutralization and HIA, according to standard methods [16], at
the Centre for Infections, Health Protection Agency (London,
UK) using egg-grown NIBRG-121 virus, a reverse-genetic virus
containing hemagglutinin and neuraminidase from the in-
fluenza A/California/7/2009 strain (seed virus kindly provided
by National Institute for Biological Standards and Control). Se-
rum samples obtained from subjects were tested with the use of
1:2 serial dilutions. For HIAs, serum samples were treated with
receptor-destroying enzyme (RDEII; Denka Seiken) according
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to the manufacturer’s instructions and tested at an initial di-
lution of 1:8, and those samples that had results that were
negative for the hemagglutinin antibody were assigned a titer of
1:4. Serum specimens were analyzed to determine absolute end
point titers, and the final dilution was 1:32,768. For micro-
neutralization assays, serum samples were tested at an initial
dilution of 1:10, and those samples that had negative results were
assigned a titer of 1:5. The final dilution was 1:320, and samples
for which the end point titers were greater were assigned a value
of 1:640. Specimens were tested in duplicate, and the geometric
mean titers were used in the analyses.
Statistical Analysis
Geometric mean titers of antibodies between groups were
compared using the analysis of variance test. Seroconversion and
seroprotection rates after vaccination were compared using the
v2 test. Seroconversion rates measured by HIA or
microneutralization assays were compared using a j correlation.
A logistic regression model was used to describe the inde-
pendent variables associated with vaccine response measured
by the HIA. Variables of interest for SOT recipients included
age, sex, time from transplantation, creatinine level, type of
organ transplanted, induction therapy, and maintenance
therapy. Statistical analysis was performed by PASW Statistics
18 software (SPSS).
RESULTS
Patient Population
A total of 89 subjects were enrolled in the study between No-
vember and December 2009; 29 SOT recipients (25 kidney
transplant recipients and 4 liver transplant recipients), 30 HIV-
infected individuals, and 30 healthy control subjects. Baseline
Table 1. Baseline Characteristics of Solid-Organ Transplant (SOT) Recipients, Human Immunodeficiency Virus (HIV)–Infected Patients,
and Control Subjects
Variable
SOT recipients
(n 5 29)
HIV-infected
patients (n 5 30)
Control subjects
(n 5 30) P
Age, mean years (6 SD) 47.7 6 12.8 48.0 6 9.8 41.8 6 8.91 .04
Sex, M/F 15/14 23/7 13/17 .02
Previous seasonal influenza vaccine
(2009), no. (%) of subjects
21 (72) 24 (80) 21 (70) .85
Time from transplant, median months (range) 38 (5–231)
Type of transplant, no. (%) of subjects
Kidney 25 (86)
Liver 4 (14)
Induction therapy, no. (%) of subjects
Thymoglobulin 12 (41)
Basiliximab 15 (52)
None 3 (10)
Maintenance immunosuppression, no. (%) of subjects
Prednisone 16 (55)
Tacrolimus 22 (76)
Cyclosporin 5 (17)
Mycophenolate 21 (72)
Azathioprine 4 (14)
mTOR inhibitor 2 (7)
Time from HIV infection diagnosis, years; median (range) 13 (1–29)
Nadir CD41 T cell count, median cells/mL (range) 181 (2–464)
Current CD41 T cell count, median cells/mL (range) 587 (312–1368)
Current undetectable viral load, no. (%) of patients 29 (97)
Patients receiving antiretroviral therapy, no. (%) of subjects
Type of antiretroviral therapy 30 (100)
NRTI 1 NNRTI 13 (43)
NRTI 1 PI 9 (30)
NRTI 1 NNRTI 1 PI 3 (10)
Other 5 (17)
NOTE. mTOR, mammal target of rapamycine; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI: nucleoside reverse-transcriptase inhibitor; PI:
protease inhibitor.
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characteristics of the patients are shown in Table 1. Control
subjects were younger than the other groups, and there were
more male subjects included in the HIV-infected group.
Overall, 66 (74%) of 89 subjects had previously received the
seasonal influenza vaccine (72% in the SOT group, 80% in
the HIV-infected group, and 70% in the control group) and 7
(7.9%) of 89 received both vaccines (seasonal and pandemic
influenza) simultaneously.
Ninety percent of SOT recipients had received induction
therapy at the time of transplantation with either thymoglobulin
or basiliximab, and most of the patients received a maintenance
combination therapy with tacrolimus and mycophenolate, with
or without steroids. All HIV-infected individuals were receiving
antiretroviral therapy at the time of vaccination, and 97% of
them had undetectable viral load.
Safety of the Influenza A H1N1/09 Vaccine
A majority of patients who received the vaccine experienced an
adverse event (90% in the control group, 93% in the HIV-
infected group, and 97% in the SOT group), although most of
the reactions were considered to be mild and resolved without
sequellae (Table 2). Patients who simultaneously received both
seasonal and pandemic influenza vaccines did not develop more
adverse events than did patients who received only the pandemic
influenza vaccine (data not shown). Only 4 patients experienced
an adverse event that was considered to be severe: 1 patient in
the HIV-infected group experienced severe fatigue after each
dose of vaccine, 2 patients in the control group also experienced
severe fatigue, and 1 patient in the control group experienced an
induration at the site of injection. Interestingly, 1 of the control
subjects who experienced fatigue also had fever, and antibody
levels before vaccination were elevated (1:512) in this patient;
therefore, it is possible that this patient may have been infected
coincidently by influenza.
Immunogenicity of the Influenza A H1N1/09 Vaccine
The results regarding the immunogenicity of the vaccine are
summarized in Table 3. A higher percentage of SOT recipients
had detectable antibody levels at baseline (24% of SOT recipi-
ents, compared with 13% of HIV-infected individuals and 3% of
control subjects, as measured by HIA; P 5 .06). Figure 1 shows
the date of enrollment in the study according to patient group
and the presence of antibody before vaccination.
Overall, HIV-infected patients and control subjects had
a higher rate of seroconversion after vaccination than did SOT
recipients. The administration of a second dose of the vaccine
did not improve the rate of seroconversion among SOT recip-
ients as measured by HIA.Most patients reached a seroprotected
status after 1 dose of the vaccine, ranging from 72% to 96% in
SOT recipients and from 80% to 100% in HIV-infected in-
dividuals (measured by HIA and by the microneutralization
assay, respectively). Geometric means of antibody titers were
comparable between groups, although there was a trend towards
higher titers in HIV-infected patients (especially as measured by
microneutralization assay). There were no significant differences
in geometric means antibody titers between day 21 and day
49 for any group. Reverse cumulative distribution of antibody
titers according to patient group and the assay used is shown in
Figure 2.
We compared the seroconversion rate at day 49 for all sub-
jects according to the test used. Twelve patients seroconverted by
HIA but not by microneutralization assay, and 4 patients sero-
converted by microneutralization assay but not by HIA. The
overall agreement between tests was 82%, with a j-value of .51
(P , .001), indicating a moderate agreement.
Variables associated with Vaccine Response
Because only 4 patients in the HIV-infected group and 7 patients
in the control group did not respond to the vaccine, we analyzed
Table 2. Adverse Events within the Week after Administration of Influenza Vaccine
SOT recipients
(n 5 29)
HIV-infected patients
(n 5 30)
Control subjects
(n 5 30) P
Variable After first
dose
After second
dose
After first
dose
After second
dose
After first
dose
Total adverse events, no. (%) of subjects 28 (97%) 20 (69%) 28 (93%) 22 (73%) 27 (90%) 0.38
Local adverse events, no. (%) of subjects 25 (86%) 17 (59%) 25 (93%) 18 (60%) 27 (90%) 0.16
Redness, total no. of subjects (mild/moderate/severe) 2 (0/2/0) 1 (1/0/0) 5 (5/0/0) 4 (3/1/0) 3 (2/1/0)
Induration, total no. of subjects (mild/moderate/severe) 6 (5/1/0) 5 (4/1/0) 12 (10/2/0) 9 (9/0/0) 16 (10/5/1)
Tenderness, total no. of subjects (mild/moderate/severe) 25 (18/7/0) 17 (13/4/0) 25 (16/9/0) 16 (12/4/0) 27 (16/11/0)
Systemic adverse events, no. (%) of subjects 19 (65%) 10 (34%) 16 (53%) 11 (37%) 16 (53%) 0.31
Fever, no. of subjects 2 2 2 0 3
Nausea, total no. of subjects (mild/moderate/severe) 4 (2/2/0) 3 (3/0/0) 2 (2/0/0) 2 (2/0/0) 3 (3/0/0)
Fatigue, total no. of subjects (mild/moderate/severe) 18 (10/8/0) 10 (8/2/0) 15 (6/8/1) 8 (6/1/1) 16 (7/7/2)
Other, total no. of subjects (Mild/Moderate/Severe) 3 (3/0/0) 5 (5/0/0) 7 (7/0/0) 5 (4/1/0) 9 (9/0/0)
NOTE. A patient may present .1 adverse event. SOT, solid-organ transplant.
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Table 3. Geometric Mean Titers Measured by Hemagglutinin Inhibition Assay and by Microneutralization Assay before and after Influenza Vaccination
Hemagglutinin inhibition assay Microneutralization assay
Variable
SOT recipient
(n 5 29)
HIV-infected
patients
(n 5 30)
Control
subjects
(n 5 30) P
SOT
recipients
(n 5 29)
HIV-infected
patients
(n 5 30)
Control
subjects
(n 5 30) P
Seroconversion rate, %
of subjects
Day 21 52 77 67 .12 52 83 97 ,.001
Day 49 52 87 77 .009 65 90 87 .03
Geometric mean titer (95%
confidence interval)
Day 0 8.6 (5.1–14.6) 5.9 (4.2–8.1) 5.9 (3.9–8.9) .35 64.8 (41.8–100.5) 28.6 (19.6–41.9) 11.8 (7.0–19.8) ,.001
Day 21 54.8 (27.3–110.0) 97.0 (46.3–203.2) 75.2 (32.5–173.7) .64 274.6 (182.9–412.3) 360.8 (255.6–509.2) 366.1 (228.2–587.3) .31
Day 49 56.8 (28.6–112.9) 116.7 (68.2–199.7) 79.7 (39.1–162.5) .61 322.6 (232.2–448.0) 500.7 (409.3–612.4) 323.7 (197.8–529.6) .06
Seroconversion factor (95%
confidence interval)
Day 21 6.4 (3.1–13.1) 16.5 (8.0–33.9) 16.2 (7.3–35.8) .12 4.2 (2.3–7.9) 13.0 (8.3–20.6) 31.1 (18.6–51.9) ,.001
Day 49 6.6 (3.2–13.7) 19.9 (11.3–34.9) 15.3 (7.7–30.2) .09 5.0 (2.7–9.3) 18.1 (11.6–28.2) 27.5 (16.0–47.1) ,.001
Seroprotection rate, % of
subjects
Day 0 24 13 3 .06 72 40 17 ,.001
Day 21 72 80 70 .65 96 100 93 .36
Day 49 72 93 80 .10 100 100 93 .13
NOTE. SOT, solid-organ transplant.
252
d
C
ID
2011:52
(15
Jan
u
ary)
d
H
IV
/A
ID
S
the variables associated with vaccine response only in SOT re-
cipients. In the univariate analysis, vaccine responders were
younger, had a longer follow-up period after transplantation,
and were not receiving a triple-drug regimen (Table 4). In the
multivariate analysis, only age remained a significant factor for
vaccine response (odds ratio [OR], 0.90; 95% confidence in-
terval [CI], 0.83–0.98 for each increase of 1 year; P 5 .021).
Outcomes at 6 Months
No patient developed clinically or microbiologically docu-
mented influenza A H1N1/09 infection during the follow-up
period. A kidney transplant recipient received a diagnosis of
breast cancer after receiving the second dose of the vaccine, and
a liver transplant recipient developed a transitory ischemic at-
tack between receiving the first and the second dose of the
vaccine. No episode of acute rejection was diagnosed in SOT
recipients during the 6-month follow-up period after vaccina-
tion. No HIV-infected individual developed an opportunistic
infection after vaccination.
DISCUSSION
In this prospective study, we assessed the immunogenicity and
safety of the influenza A H1N1/09 A03-adjuvanted vaccine in
immunocompromised patients, and we compared the results to
those for a control group of healthy volunteers. We observed
a similar response in antibody levels in HIV-infected individuals,
compared with the response in control subjects, whereas the
response in SOT recipients was lower, overall, than was the
response in the other 2 groups. Of note, all groups reached the
recommended target for vaccine approval according to the
EMEA after receipt of the first dose of vaccine. Improvement in
the vaccine response was only moderate after administration of
the second dose of the vaccine in the HIV group.
A number of studies have evaluated the immunogenicity of
the influenza A H1N1/09 vaccine in different populations,
mostly in immunocompetent adults and children [9–14]. Most
studies have found an appropriate response to the vaccine using
both adjuvanted and nonadjuvanted vaccines, although a higher
response was generally seen with adjuvanted vaccines. For ex-
ample, seroconversion rates after 1 dose of 15 lg of non-
adjuvanted vaccine was 63%–72% in a cohort of 176 adults,
whereas the response to 7.5 lg of MF59-adjuvanted vaccine was
77%–96% [9]. A randomized trial involving 937 children from 6
months to 13 years of age [12] showed a better immunogenicity
associated with receipt of 2 doses of 1.875 lg of the AS03-
adjuvanted vaccine than with receipt of 2 doses of 7.5 lg of the
nonadjuvanted vaccine (98% vs 80% in children,3 years of age
and in 99% vs 95% in those .3 years of age). In this trial,
systemic reactions were more commonly seen in association
with receipt of the adjuvanted vaccine, although serious adverse
events were rare [12]. In our study, the control group had
a lower response rate to the vaccine than was expected (67%
seroconversion rate at day 21, measured by HIA). It is not clear
why we observed this slightly lower-than-expected response,
although it may be attributable to the relatively modest sample
size of our study.
Experience with the influenza A H1N1/09 vaccine in immu-
nocompromised patients is limited, because the immunoge-
nicity of the vaccine has only been evaluated in HIV-infected
Figure 1. Date of vaccination according to patient group. The red line shows the week when the influenza A H1N1/09 pandemic reached its peak in
Switzerland (Swiss Federal Office of Public Health) Grippe pande´mique (H1N1) 2009 en Suisse, semaines 17 (2009) a` 8 (2010). Bull OFSP 2010; no 20: 535-
543. Numbers inside the columns denote the number of patients with detectable antibodies before vaccination. SOT, solid-organ transplant.
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individuals [15]. Bickel et al [15] observed a 69% seroconversion
rate among 160 HIV-infected individuals who received 1 dose of
the AS03-adjuvanted influenza vaccine, which was the same
vaccine used in our study. Variables associated with a favorable
vaccine response included younger age and higher CD41 T cell
count. Compared with their findings, we observed an 8% higher
seroconversion rate in our cohort of treated HIV-infected pa-
tients after receipt of 1 dose of the vaccine. Regarding SOT
Table 4. Variables associated with Vaccine Response in the Group of Solid-Organ Transplant (SOT) Recipients
Variable Responders (n 5 15) Nonresponders (n 5 14) P
Age, mean years (6SD) 41.9 6 14.2 54.3 6 7.1 .006
Sex, M/F 8/7 7/7 ..99
Time from transplant, median months 78 19 .07
Creatinine, mean lmol/L (6SD) 122.4 6 37.8 126.4 6 47.5 .39
Type of transplant, no. of patients .037
Kidney 11 14
Liver 4 0
Induction therapy, patients .36
Thymoglobulin 5 7
No thymoglobulin 10 7
Maintenance immunosuppression, patients
Triple therapya 5 10 .04
Dual or monotherapy 10 4
a Calcineurine inhibitor (cyclosporine or tacrolimus) plus prednisone plus antimetabolite (mycophenolate or azathioprine).
Figure 2. Reverse cumulative-distribution curves of antibody titers measured by hemagglutinin inhibition assay in serum samples obtained on day 21
(A) and on day 49 (B) and measured by microneutralization in serum samples obtained on day 21 (C) and on day 49 (D), according to the patient population.
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recipients, no studies have been published, to our knowledge,
that have assessed the immunogenicity of the influenza A H1N1/
09 vaccine.
The AS03-adjuvanted vaccine was, overall, well-tolerated in
the 3 groups. Safety was a potential concern for SOT recipients,
because experience with adjuvanted influenza vaccines is limited
in this population, and some clinicians were reluctant to use
adjuvanted influenza vaccines in this population because of the
possible risk for acute rejection. In addition, recent data suggest
that influenza vaccination can temporarily increase nonspecific
cellular alloreactivity in SOT recipients[17]. This has not been
observed in our study, nor has it been observed in previous
studies that have used MF59-adjuvanted seasonal influenza
vaccine in kidney and heart transplant recipients [18, 19]. Several
recent studies with nonadjuvanted influenza vaccine also pro-
vide evidence against an association between influenza vaccina-
tion and immunologic dysregulation in SOT recipients [20, 21].
A significant proportion of patients in our study had test
results that were positive for antibodies before vaccination. Al-
though, especially in older patients, this can be the result of
a cross-reactivity with nonpandemic influenza H1N1 infection
[22], it may also represent the consequence of previously un-
recognized infection [23], because the vaccination campaign in
Switzerland was performed during the peak of the pandemic
influenza season. The group that includedmore individuals with
preexisting antibodies was the SOT recipient group, which in-
cluded more individuals who were enrolled slightly later in the
study (although patients who were seropositive for antibodies
before vaccination included individuals who were enrolled
throughout the inclusion period). The baseline seroprotection
rate was high in the SOT group (76%) when the antibody re-
sponse was measured by microneutralization assay. In addition,
seroconversion rates were also higher when measured by mi-
croneutralization assay than when measured by HIA. This may
be explained by the fact that the HIA only measures the pro-
portion of antibodies that are directed to the receptor-binding
site of viral hemagglutinin, whereas the microneutralization
assay detects a broader range of neutralizing antibodies. How-
ever, only the HIA has been correlated with vaccine protection
[24]. A higher rate of seroprotection against influenza A H1N1
when measured by the microneutralization assay was also seen
in a serological survey in England [23].
We evaluated the variables associated with vaccine response in
the group of SOT recipients. In the multivariate analysis,
a younger age was the only variable significantly associated with
vaccine response, which is a consistently recognized factor for
a favorable vaccine response. Regarding the influenza A H1N1/
09 vaccine, a recent study that also used the AS03-adjuvanted
vaccine showed that immunogenicity was better in healthy adults
,60 years of age than it was in older individuals [25]. In addi-
tion, a large trial in China that used the nonadjuvanted vaccine
also showed a lower rate of seroprotection among the elderly
population (79%) than among younger adults (97%) [11].
Our study has several limitations. First, this was not a ran-
domized trial, and therefore we did not control for the vaccine
administration. For example, a significant number of patients
simultaneously received the seasonal vaccine, and this may have
influenced the antibody response to the influenza A H1N1/09
vaccine. However, this was not seen in a randomized trial that
involved 355 patients [26], in which immunogenicity of the
pandemic influenza vaccine was similar irrespective of whether
the patient had simultaneously received the seasonal vaccine.
Second, we enrolled 2 different groups of immunocompromised
patients (likely with different net states of immunosuppression);
therefore, extrapolation of these results to other immunocom-
promised populations should be done with caution. Indeed,
treated HIV-infected individuals can elicit a response similar to
that for healthy control subjects, and we would expect a lower
vaccine response rate among HIV-infected individuals with low
CD41 T cell counts [27]. However, the information derived
from our study is useful, because it encourages the use of the
influenza vaccine in similar patients.
In conclusion, the immunogenicity of the influenza A H1N1/
09 AS03-adjuvanted vaccine was appropriate in all 3 groups,
although higher responses were observed among treated HIV-
infected patients and healthy control subjects. A second dose of
the vaccine only slightly improved the immunogenicity, and
therefore, a single dose would probably be more cost-effective in
large-scale vaccinations. However, additional data from larger
studies would be needed to confirm our results. These data on
influenza A H1N1/09 have practical implications for strategies
surrounding influenza vaccination in specific immunocom-
promised patients during the next influenza season.
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